PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB co	ntrol number.					
	Substitute for form 1449/PTO INFORMATION DISCLOSURE				Complete if Known	OPA
				Application Number	10/596,429	/
STATEMENT BY APPLICANT			PLICANT	Filing Date	12/17/2004	Mar. 3
	Date Submitted: May 3, 2010			First Named Inventor	Norihiro NISHIMOTO	MAY 0 3 2010
				Art Unit	1647	d
(use as many sheets as necessary)			necessary)	Examiner Name	Lorraine Spector	13.
Sheet	1	of	1	Attorney Docket Number	053466-0417	PADEMARKON

U.S. PATENT DOCUMENTS					
Examin er Initials*	Cite No.1	Document Number Number-Kind Code ² (if	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
initials		known)			Figures Appear
	-			-	

FOREIGN PATENT DOCUMENTS					
Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		No.1 Country Code "Number*	Cite Foreign Patent Document No. Country Code*Number* MM-DD-YYYY	Cite Foreign Patent Document No. 1 Country Code*Number* Publication Date Name of Patentee or Applicant of Cited Documents	Cite Foreign Patent Document No. Country Code*Number* Publication Date Name of Patentee or Applicant of Cited Documents Pages, Columns, Lines, Where Relevant Pages, Columns, Lines, Where Relevant

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, cit) and/or country where published.	T ⁶		
	F1	BELLOMO, R., "Tye Cytokine Network in the Critically III," Anaesthesia and Intensive Care, August 1992, 20(3):288-302.			
-	F2	MURATA et al., "Development mechanism and pathophysiology," The Saishin-Igaku, Special Issue: A new point of view in pancreatic diseases, November 1992, 47(11):49-56, with English translation, 17 pages.	V		
	F3	ULICH et al., "Intratracheal Injection of Endotoxin and Cytokines," American Journal of Pathology, May 1991, 138(5):1097-1101.			
			L		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature	/Lorraine Spector/	Date Considered	09/02/2010	
CVANISCE Initial if reference considered whether or not states to be conformated with MDED COD. Draw line through citation if not be conformated and not				

"EXAMINEE: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation in four in conformance and not considered, include copy of this form with next communication to applicant 1 Applicant's unique custation designation unimber (optional) 2 See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04.3 Einter Office that issued the document, by the two-letter code (WIPO Standard ST.3).4 For Jaganese patient fourcoments, the indication of the year of the region of the Empire or wast precede the section number of the patient documents and the patient documents are included in the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language

This collection of information is required by 3T CFR. 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to proceed) an application. Confidentially is governed by 3G U.S. C12 and 3T CFR. 1.4 This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of the you require to complete its from and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2231-1450 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: